Thu, December 13, 2012
Wed, December 12, 2012
Tue, December 11, 2012
Mon, December 10, 2012
Sun, December 9, 2012
Sat, December 8, 2012
Fri, December 7, 2012
Thu, December 6, 2012
Wed, December 5, 2012
Tue, December 4, 2012
Mon, December 3, 2012
Sun, December 2, 2012
Sat, December 1, 2012
Fri, November 30, 2012
Thu, November 29, 2012
Wed, November 28, 2012
Tue, November 27, 2012
Mon, November 26, 2012
Sun, November 25, 2012
Fri, November 23, 2012
Thu, November 22, 2012
Wed, November 21, 2012
Tue, November 20, 2012
Mon, November 19, 2012
Sat, November 17, 2012

Depomed To Present At Oppenheimer 2012 Healthcare Conference


//health-fitness.news-articles.net/content/2012/ .. t-at-oppenheimer-2012-healthcare-conference.html
Published in Health and Fitness on Monday, December 3rd 2012 at 13:45 GMT by Market Wire   Print publication without navigation


Depomed To Present At Oppenheimer 2012 Healthcare Conference -- NEWARK, Calif., Dec. 3, 2012 /PRNewswire/ --

NEWARK, Calif., Dec. 3, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: [ DEPO ]) today announced that it will be presenting at the Oppenheimer 23rd Annual Healthcare Conference at the Waldorf Astoria Hotel in New York City.

The presentation at the Oppenheimer conference is scheduled for 10:35 am EST (7:35 am PST) on Wednesday, December 12, 2012.  The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at [ www.depomed.com ].  A recording of the webcast will be archived for 30 days on the company's website.

About Depomed
Depomed, Inc. is a specialty pharmaceutical company with three approved and marketed products. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN).  Zipsor ®(diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults.  Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States.  Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food.  Additional information about Depomed may be found on its website, [ www.depomed.com ].

CONTACT:
August J. Moretti
Depomed, Inc.
510-744-8000
[ amoretti@depomed.com ]

SOURCE Depomed, Inc.



RELATED LINKS
[ http://www.depomed.com ]

Publication Contributing Sources